Bulletin
Investor Alert

Market Pulse Archives

Sept. 16, 2020, 8:17 a.m. EDT

Analyst: Vaccines can sometimes trigger rare disorder reportedly identified in AstraZeneca trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The participant in AstraZeneca's /zigman2/quotes/200304487/composite AZN +5.29% /zigman2/quotes/203048482/delayed UK:AZN +6.15% Phase 3 study of its experimental COVID-19 vaccine who triggered the clinical trial's hold reportedly was diagnosed with transverse myelitis, which is a spinal disorder potentially associated with vaccines, according to RBC Capital Markets' Brian Abrahams. AstraZeneca's stock was up 0.9% in premarket trading on Thursday. The New York Times first reported the diagnosis of transverse myelitis, which has not been confirmed by AstraZeneca; however, the company has confirmed it halted the trial due to a "potentially unexplained illness." Abrahams wrote in a note on Tuesday to investors that instances of vaccine-related transverse myelitis are rare, though there are 119 cases recognized by the Food and Drug Administration between 1985 and 2017. "It makes sense that the [adverse event] will be fully investigated prior to continuation of vaccine administration," he wrote. "It also highlights the importance of following volunteers for weeks to months post-dosing, as if this side effect were actually related to this or other COVID-19 vaccinations." Shares of AstraZeneca, which is developing the vaccine with the University of Oxford, are up 7.6% so far this year. The S&P 500 /zigman2/quotes/210599714/realtime SPX -1.70% has gained 5.2%.

/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 58.50
+2.94 +5.29%
Volume: 17.49M
Sept. 20, 2021 4:00p
P/E Ratio
40.84
Dividend Yield
2.34%
Market Cap
$171.71 billion
Rev. per Employee
$362,602
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
8,559.00 p
+496.00 +6.15%
Volume: 3.93M
Sept. 20, 2021 4:35p
P/E Ratio
40.33
Dividend Yield
2.36%
Market Cap
£124.91 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,357.73
-75.26 -1.70%
Volume: 2.60B
Sept. 20, 2021 5:09p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.